CD274 and neoplasm: While no specific molecular targets have been identified, future immunohistochemical analyses indicating high PD-L1 expression or increased tumor mutational burden may support the use of PD-1/PD-L1 inhibitors in combination with chemotherapy to improve treatment outcomes in HGASC (20).